Cerecor Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Baltimore MD United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2012
NCT01579526
First Marketed Drug
2013
rabeprazole (pariet)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cerecor Inc | CERECOR INC

Active Ingredients

Marketed Drugs (1)

rabeprazole (pariet) (2013)

Drugs in Phase 3 Trials (1)

Key: Cerecor Inc (0) Acquired (1)

fasoracetam (4 trials)

Drugs in Phase 2 Trials (8)

Key: Cerecor Inc (3) Acquired (5)

aevi-001 (2 trials)

autologous skin graft (1 trial)

cerc-002 (1 trial)

cerc-301 (2 trials)

cerc-501 (2 trials)

epoetin (Epogen) (1 trial)

fp01 (3 trials)

mdgn201 (3 trials)

Drugs in Phase 1 Trials (3)

Key: Cerecor Inc (1) Acquired (2)

aevi-007 (2 trials)

cerc-006 (1 trial)

mdgn-002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cough (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Respiratory Tract Infections (Phase 2)

Suicidal Ideation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 23
  • # of Trial APIs: 12